Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
The latest update is out from XORTX Therapeutics Inc ( (TSE:XRTX) ).
On January 17, 2025, XORTX Therapeutics Inc. announced a change in auditors, appointing Davidson & Company LLP as the new auditor effective January 16, 2025, following the resignation of Smythe LLP. The transition was smooth, with no reservations in past audit reports and no ‘reportable events’ noted. This change reflects XORTX’s ongoing commitment to maintaining transparent and effective financial oversight, potentially strengthening its position within the pharmaceutical industry.
More about XORTX Therapeutics Inc
XORTX Therapeutics Inc. is a late-stage clinical pharmaceutical company focused on developing innovative therapies for progressive kidney disease and gout. The company is currently advancing three clinically advanced products, including XRx-008 for ADPKD, XRx-026 for allopurinol intolerant gout, and XRx-101 for acute kidney and other acute organ injuries associated with COVID-19. Additionally, XRx-225 is in pre-clinical development for Type 2 Diabetic Nephropathy.
YTD Price Performance: -8.73%
Average Trading Volume: 3,541
Technical Sentiment Consensus Rating: Strong Buy
Current Market Cap: C$5.27M
See more data about XRTX stock on TipRanks’ Stock Analysis page.
